Eligibility

We are collecting reports on adult patients (18 and older) with a current or historical invasive solid or hematologic malignancy who have been diagnosed with COVID-19, with or without laboratory confirmation of SARS-CoV-2 infection. Reporting is anonymous and all reported data must be de-identified. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.

Healthcare providers (or their proxies) from the United States, the European Union (EU), Argentina, Canada, and the United Kingdom (UK) are eligible to report cases. If you don't see your country or region on this list, keep checking back - we are actively working to expand internationally.

Participating institutions

About Us

CCC19

We are a consortium of over 100 cancer centers and other organizations who have come together to collect data about patients with cancer who have been diagnosed with COVID-19.

The driving goal of the CCC19 consortium is to collect and disseminate prospective, granular, uniformly organized information on people with cancer who are diagnosed with COVID-19 – at scale and as rapidly as possible.